Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder
Pharma Shelves One Drug Program, Narrows Another
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.
